Physician

Stephan B Rosenfeld, M.D.

According to 2025 Medicare claims, Stephan Rosenfeld, M.D. (NPI: 1083685283) practices medical oncology in the Fayetteville-Springdale-Rogers, AR market, with the plurality of this provider's patient population coming from Washington, AR. This provider's primary affiliated billing organization is HIGHLANDS ONCOLOGY GROUP PA (NPI: 1346211323; TIN: 710788742) and primary practice location at 72758-8602. Rosenfeld is affiliated with the Mercy Health ACO, LLC (ACO ID: A2616), participating under the MSSP model.

Rosenfeld's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,611 traditional Medicare patients, billed 267,464 HCPCS/CPT codes, and received $4,871,061 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,947 prescription claims across 472 beneficiaries totaling $6,353,604 in drug costs, led by Ibrance (Palbociclib). DME data shows 98 claims. Open Payments data shows 85 records totaling $8,879. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $819,188 to $6,353,604. In contrast, DME billing represents a smaller volume and moved up and down with repeated peaks and valleys, starting at $10,280 and ending at $14,474.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,435	235,777	$3,674,118
2016	1,657	360,951	$5,221,540
2017	1,659	305,404	$4,442,185
2018	1,740	321,718	$4,326,467
2019	1,705	380,202	$4,886,876
2020	1,587	278,900	$4,795,072
2021	1,728	297,034	$4,676,498
2022	1,690	343,794	$5,628,840
2023	1,523	287,445	$4,292,692
2024	1,611	267,464	$4,871,061

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	609	3,296	$819,188
2016	680	3,656	$1,343,398
2017	654	3,224	$1,784,311
2018	624	2,709	$1,877,106
2019	680	2,629	$1,876,685
2020	655	2,240	$2,081,639
2021	562	1,856	$1,904,687
2022	515	1,785	$1,871,298
2023	533	1,769	$2,154,699
2024	472	1,947	$6,353,604

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	13	227	$67,631
2016	13	126	$36,195
2017	26	111	$13,293
2018	13	78	$6,638
2019	14	62	$7,193
2020	11	132	$8,991
2021	18	63	$3,752
2022	14	32	$2,722
2023	N/R	153	$18,928
2024	16	98	$3,700

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	583	1,255	$86
80053	Blood test, comprehensive group of blood chemicals	611	1,520	$10
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	840	2,079	$8
83735	Magnesium level	567	1,462	$7
84550	Uric acid level, blood	566	1,480	$4

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Ibrance	Palbociclib	142	3,969	$2,255,510
Imbruvica	Ibrutinib	43	1,204	$703,682
Idhifa	Enasidenib Mesylate	16	480	$561,970
Calquence	Acalabrutinib Maleate	33	990	$497,371
Inlyta	Axitinib	20	600	$488,108

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
L8000	Breast prosthesis, mastectomy bra, without integrated breast prosthesis form, any size, any type	N	16	17	$1,438
E1390	Oxygen concentrator, single delivery port, capable of delivering 85 percent or greater oxygen concentration at the prescribed flow rate	Y	N/R	13	$1,066
J8521	Capecitabine, oral, 500 mg	N	N/R	16	$546
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	14	$263
A4456	Adhesive remover, wipes, any type, each	N	N/R	14	$155

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	85	$8,879	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Stephan B. Rosenfeld, M.D.?

Tedicare shows public-source Medicare data for Stephan B. Rosenfeld, M.D. (NPI 1083685283), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Stephan B. Rosenfeld, M.D. have ACO affiliation data?

Stephan B. Rosenfeld, M.D. is shown with ACO affiliation data for Mercy Health ACO, LLC (MSSP, ACO ID A2616).

What billing organization is linked to Stephan B. Rosenfeld, M.D.?

Stephan B. Rosenfeld, M.D. is linked to HIGHLANDS ONCOLOGY GROUP PA (billing NPI 1346211323) in the available physician profile data.

Does Stephan B. Rosenfeld, M.D. have Open Payments data?

Stephan B. Rosenfeld, M.D. has 85 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.